A Multicentre, Prospective, Non-Interventional, Post-Authorisation Study Evaluating the Safety and Effectiveness of a Fixed-Dose Fluticasone/Formoterol (FP/FORM ) Pressurised Metered-Dose Inhaler in Patients with Asthma

Trial Profile

A Multicentre, Prospective, Non-Interventional, Post-Authorisation Study Evaluating the Safety and Effectiveness of a Fixed-Dose Fluticasone/Formoterol (FP/FORM ) Pressurised Metered-Dose Inhaler in Patients with Asthma

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Oct 2017

At a glance

  • Drugs Formoterol/fluticasone propionate (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mundipharma GmbH
  • Most Recent Events

    • 01 Oct 2017 Primary endpoint (Asthma control) has been met, according to results published in the Respiratory Medicine Journal.
    • 01 Oct 2017 Results published in the Respiratory Medicine Journal.
    • 05 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top